IntegraFin Holdings plc (LON:IHP – Get Free Report) insider Jonathan Gunby bought 41 shares of the business’s stock in a transaction on Monday, September 23rd. The stock was bought at an average cost of GBX 360 ($4.82) per share, for a total transaction of £147.60 ($197.64).
Jonathan Gunby also recently made the following trade(s):
- On Monday, July 22nd, Jonathan Gunby purchased 41 shares of IntegraFin stock. The stock was bought at an average cost of GBX 372 ($4.98) per share, with a total value of £152.52 ($204.23).
IntegraFin Stock Down 2.1 %
Shares of IHP stock traded down GBX 8 ($0.11) during trading hours on Tuesday, hitting GBX 364.50 ($4.88). 327,438 shares of the company were exchanged, compared to its average volume of 408,822. IntegraFin Holdings plc has a 52 week low of GBX 208.73 ($2.79) and a 52 week high of GBX 395 ($5.29). The company has a current ratio of 8.80, a quick ratio of 0.01 and a debt-to-equity ratio of 1.73. The business has a 50 day moving average of GBX 374.01 and a two-hundred day moving average of GBX 333.85. The company has a market capitalization of £1.21 billion, a PE ratio of 2,268.75, a PEG ratio of 3.14 and a beta of 1.15.
Wall Street Analysts Forecast Growth
View Our Latest Analysis on IHP
About IntegraFin
IntegraFin Holdings plc, together with its subsidiaries, provides an investment platform for UK financial advisers and their clients. It operates through Investment administration services, Insurance and life assurance business, and Adviser back-office technology segments. The company operates Transact, a wrap platform that enable advisers to consolidate their clients investments using tax efficient wrappers and provide range of investment choice; and Time4Advice (T4A), an adviser practice management solution.
Featured Articles
- Five stocks we like better than IntegraFin
- What Are Dividend Challengers?
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Business Services Stocks Investing
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Energy and Oil Stocks Explained
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for IntegraFin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntegraFin and related companies with MarketBeat.com's FREE daily email newsletter.